Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
150%(6 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (50.0%)
Phase 24 (50.0%)

Trials by Status

completed450%
terminated338%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

NCT01907607
completedphase_1

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

NCT02101034
completedphase_2

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409
terminatedphase_1

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

NCT01111188
unknownphase_1

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

NCT02202200
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01907607Phase 2

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Completed
NCT02101034Phase 1

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Completed
NCT00721409Phase 2

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Completed
NCT01111188Phase 1

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Terminated
NCT02202200Phase 1

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Unknown
NCT01227434Phase 2

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

Terminated
NCT00555906Phase 2

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Completed
NCT01701375Phase 1

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8